The financials
Agios Pharmaceuticals, Inc. by the numbers
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $21M in Q1 2026 (quarter ended March 31, 2026), up 138% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $99M. For the full year FY2025, revenue was $54M (+48% year on year) and net income −$413M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $21M | $8.7M | +138% |
| Gross profit | $19M | $7.6M | +154% |
| Operating income | −$110M | −$107M | n/a |
| Net income | −$99M | −$89M | n/a |
| Diluted EPS | −$1.69 | −$1.55 | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $0.00
Segment Latestyear on year